Abstract：
Myeloid-Derived Suppressor Cells (MDSCs) are a heterogeneous population of immature myeloid cells that play important roles in maintaining immune homeostasis and regulating immune responses. MDSCs can be divided into two main subsets based on their surface markers and functional properties: granulocytic MDSCs (G-MDSCs) and monocytic MDSCs (M-MDSCs). Recently greatest attention has been paid to innate immunity in Multiple Sclerosis (MS), so the aim of our review is to provide an overview of the main characteristics of MDSCs in MS and its preclinical model by discussing the most recent data available. The immunosuppressive functions of MDSCs can be dysregulated in MS, leading to an exacerbation of the autoimmune response and disease progression. Antigen-specific peptide immunotherapy, which aims to restore tolerance while avoiding the use of non-specific immunosuppressive drugs, is a promising approach for autoimmune diseases, but the cellular mechanisms behind successful therapy remain poorly understood. Therefore, targeting MDSCs could be a promising therapeutic approach for MS. Various strategies for modulating MDSCs have been investigated, including the use of pharmacological agents, biological agents, and adoptive transfer of exogenous MDSCs. However, it remained unclear whether MDSCs display any therapeutic potential in MS and how this therapy could modulate different aspects of the disease. Collectively, all the described studies revealed a pivotal role for MDSCs in the regulation of MS..
摘要：
髓系来源的抑制细胞(MDSC)是不成熟骨髓细胞的异质群体,其在维持免疫稳态和调节免疫应答中起重要作用。基于其表面标志物和功能特性,MDSCs可分为两个主要子集:粒细胞MDSCs(G-MDSC)和单核细胞MDSCs(M-MDSC)。近年来，多发性硬化症（MS）的先天免疫受到了最大的关注，因此,我们综述的目的是通过讨论可获得的最新数据,概述MS中MDSCs的主要特征及其临床前模型.MDSCs的免疫抑制功能在MS中可能失调，导致自身免疫反应和疾病进展的恶化。抗原特异性肽免疫治疗，旨在恢复耐受性，同时避免使用非特异性免疫抑制药物，是治疗自身免疫性疾病的一种有希望的方法，但成功治疗背后的细胞机制仍然知之甚少。因此,靶向MDSCs可能是一种有前途的MS治疗方法。已经研究了调节MDSCs的各种策略，包括使用药物，生物制剂，和外源MDSCs的过继转移。然而,目前尚不清楚MDSCs是否在MS中显示出任何治疗潜力,以及该疗法如何调节疾病的不同方面.总的来说，所有描述的研究都揭示了MDSCs在调节MS中的关键作用。。
